

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7324148

|   |  |
|---|--|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                           |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                               |
| <b>CONVEYING PARTY DATA</b>   |  |
| <b>Name</b>   | <b>Execution Date</b>                    |
| ALLARITY THERAPEUTICS A/S   | 05/10/2022                               |
| <b>RECEIVING PARTY DATA</b>   |  |
| <b>Name:</b>  | ONCOLOGY VENTURE PRODUCT DEVELOPMENT APS |
| <b>Street Address:</b>  | VENLIGHEDSVEJ 1                          |
| <b>City:</b>  | HØRSBOLM                                 |
| <b>State/Country:</b>   | DENMARK                                  |
| <b>Postal Code:</b>   | 2970                                     |
| <b>PROPERTY NUMBERS Total: 8</b>  |  |
| <b>Property Type</b>  | <b>Number</b>                            |
| Patent Number:  | 8445198                                  |
| Patent Number:  | 9598734                                  |
| Application Number:   | 14119008                                 |
| Patent Number:  | 10392667                                 |
| Application Number:   | 62056295                                 |
| Patent Number:  | 10570457                                 |
| Application Number:   | 62101618                                 |
| Application Number:   | 14991080                                 |
| <b>CORRESPONDENCE DATA</b>  |  |
| <b>Fax Number:</b>  | (617)428-7045                            |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |
| <b>Phone:</b>   | 6174280200                               |
| <b>Email:</b>   | patentadministrator@clarkelbing.com      |
| <b>Correspondent Name:</b>  | CLARK+ELBING LLP                         |
| <b>Address Line 1:</b>  | 101 FEDERAL STREET, 15TH FLOOR           |
| <b>Address Line 4:</b>  | BOSTON, MASSACHUSETTS 02110              |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 50495-001001                             |
| <b>NAME OF SUBMITTER:</b>   | RICHARD TODD ARMSTRONG, PH.D.            |
| <b>SIGNATURE:</b>   | /Richard Todd Armstrong, Ph.D./          |

|   |            |
|---|------------|
| <b>DATE SIGNED:</b>   | 05/11/2022 |
| <b>Total Attachments: 5</b><br>source=50495-001001 - Confirmatory Assignment 2022#page1.tif<br>source=50495-001001 - Confirmatory Assignment 2022#page2.tif<br>source=50495-001001 - Confirmatory Assignment 2022#page3.tif<br>source=50495-001001 - Confirmatory Assignment 2022#page4.tif<br>source=50495-001001 - Confirmatory Assignment 2022#page5.tif |            |

**CONFIRMATORY ASSIGNMENT**

For valuable consideration, we, the undersigned Assignor,

| Full Name of Assignor     | State of Incorporation | Business Address                           |
|---------------------------|------------------------|--|
| Allarity Therapeutics A/S | Denmark                | Venlighedsvej 1; 2970<br>Hørsholm, DENMARK |

acknowledge the previous transfer to Assignee set forth below and to its successors and assigns (collectively hereinafter called "the Assignee"), or to the extent the entire right, title, and interest of the Assignors in, to, and deriving from the inventions disclosed in the patent(s) or application(s) set forth below have not have been transferred to Assignee do hereby assign to the Assignee

| Full Name of Assignee                    | State of Incorporation | Business Address                           |
|--|------------------------|--|
| Oncology Venture Product Development ApS | Denmark                | Venlighedsvej 1; 2970<br>Hørsholm, DENMARK |

the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more patents and applications, identified as:


| Title of Application  | Filing Date | Serial Number/<br>Patent Number |
|---|-------------|---------------------------------|
| METHODS, KITS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY  | 09-May-2008 | 8,445,198                       |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY   | 29-Oct-2012 | 9,598,734                       |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE   | 18-Dec-2013 | 14/119,008                      |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY OF FULVESTRANT IN CANCER PATIENTS                                   | 27-Aug-2019 | 10,392,667                      |
| METHODS FOR PREDICTING DRUG RESPONSIVENESS  | 26-Sep-2014 | 62/056,295                      |
| METHODS FOR PREDICTING DRUG RESPONSIVENESS  | 08-Mar-2017 | 10,570,457                      |
| METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS   | 09-Jan-2015 | 62/101,618                      |
| METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS   | 08-Jan-2016 | 14/991,080                      |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY        | 01-Dec-2006 | PCT/IB2006/004048               |
| METHODS, KITS, AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 09-May-2008 | PCT/EP2008/003789               |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY   | 29-Apr-2011 | PCT/IB2011/001405               |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE   | 01-Jun-2012 | PCT/EP2012/002332               |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY OF FULVESTRANT IN CANCER PATIENTS                                   | 05-Feb-2014 | PCT/EP2014/052236               |
| METHODS FOR PREDICTING DRUG RESPONSIVENESS  | 25-Sep-2015 | PCT/IB2015/002055               |
| METHODS FOR PREDICTING DRUG RESPONSIVENESS  | 25-Sep-2015 | EP 15820250.7                   |

|  |             |                     |
|--|-------------|---------------------|
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | AU 2011246976       |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | CA 2,800,557        |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | CH 2563936          |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | DE 2563936          |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | EP 2563936          |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | FR 2563936          |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | GB 2563936          |
| METHODS AND DEVICES FOR PREDICTING TREATMENT EFFICACY  | 29-Apr-2011 | IE 2563936          |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | CA 2,631,236        |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | CN ZL200680052220.2 |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | EP 06848658.8       |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | HK 1128496A         |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | JP 5984324          |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | JP 2014-029461      |
| METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | 01-Dec-2006 | JP 2015-183600      |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | AU 2012265177       |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | CA 2,836,836        |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | CH 2714927          |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | CN ZL201280038428.4 |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | DE 2714927          |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | EP 2714927          |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | FR 2714927          |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | GB 2714927          |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER RELAPSE  | 01-Jun-2012 | IE 2714927          |

|  |             |                    |
|--|-------------|--------------------|
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER<br>RELAPSE | 01-Jun-2012 | IN 9460/CHENP/2013 |
| METHODS AND DEVICES FOR PROGNOSIS OF CANCER<br>RELAPSE | 01-Jun-2012 | JP 6039656         |

This assignment includes said patents and applications, all applications claiming priority thereto and all divisionals, renewals, and continuations thereof, any and all United States and foreign patents, and all reissues, reexamination certificates, and extensions thereof, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said patents and applications under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment also includes the right to sue for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein, or provisional rights from any patent applications listed herein.


**ASSIGNORS:**

  
\_\_\_\_\_  
Signature

**Allarity Therapeutics A/S**

5/16/22  
\_\_\_\_\_  
Date

**Witness:**

  
\_\_\_\_\_  
Signature

**Steen Knudsen**


\_\_\_\_\_  
Printed name

**May 10, 2022**

\_\_\_\_\_  
Date

**ASSIGNEE:**

In acknowledgement of receipt of this assignment:

  
Signature \_\_\_\_\_ Date 5-10-22

Representative Name: Steve Carched

Representative Title: CEO

**Oncology Venture Product Development ApS**

Witness:

  
Signature \_\_\_\_\_

May 10, 2022

\_\_\_\_\_ Date

Steen Knudsen

\_\_\_\_\_  
Printed name